Central Nervous System
FDA halts Neumora’s schizophrenia drug trial over convulsions in rabbits
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
Norgine seeks approval for high-risk neuroblastoma treatment
Norgine has sought approval for eflornithine (difluoromethylornithine [DFMO]) for the treatment of patients with high-risk neuroblastoma (HRNB). The development marks…
Lonza links with NeuroSense to detect exosome-based biomarkers
Swiss contract manufacturer Lonza and NeuroSense Therapeutics have partnered to detect exosome-based biomarkers to bolster diagnostics and treatments for neurodegenerative…
Seaport emerges after $100m raise with ex-Karuna team at helm
Seaport Therapeutics has entered the neuropsychiatry treatment space after emerging with $100m from a financing round. ARCH Venture Partners and…
FDA gives nod to BrainStorm for ALS trial after Phase III flop
BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the…
Acumen and Lonza to produce Alzheimer’s drug sabirnetug
Acumen Pharmaceuticals has entered a strategic partnership with Swiss contract manufacturer Lonza to further the development of sabirnetug (ACU193), a…
MiNA and Nippon Shinyaku enter RNAa therapeutics deal
MiNA Therapeutics has entered a research partnership and licensing agreement with Nippon Shinyaku to develop small activating RNA (RNAa) therapeutics…
Addex spinoff Neurosterix debuts with $63m for developing neurological therapies
Swiss company Neurosterix has launched into the neurological drug development scene with $63m in Series A funding to develop allosteric…
Otsuka and Lundbeck’s schizophrenia treatment gains EC approval
The European Commission (EC) has approved Otsuka Pharmaceutical Europe and H Lundbeck's Abilify Maintena 720mg/960mg (aripiprazole) for the maintenance treatment…
AriBio licenses Alzheimer’s pill in China for up to $770m
AriBio has signed off on exclusive marketing rights for its Alzheimer’s disease treatment candidate AR1001 in China. The deal, with…
